Skip to content

Retatrutide Could Change Everything… But Who Actually Gets It?

April 21, 2026 · 30 min

Show notes

ON THE PEN RESOURCES AND LINKS: HTTPS://WWW.OTPLINKS.COM


What if the most powerful obesity drug ever created ends up being the one you can’t get?

That’s the real conversation around retatrutide right now.

In this video, I break down what Eli Lilly is doing behind the scenes, and why this isn’t just about whether retatrutide is better than tirzepatide. This is about strategy. This is about access. And this is about who gets left behind.

We’re talking about:
• The push to classify retatrutide as a biologic
• Why that could mean pricing in the $7,000/month range
• How LillyDirect is changing access to tirzepatide
• The “two lane” system that could define obesity treatment going forward
• And what this means for patients already struggling to stay on GLP-1 therapies

If you’ve ever fought insurance, dealt with compounding disappearing, or felt like the system decides what you’re allowed to have… this one is for you.

👇 Let’s talk about it
Have you ever felt stuck between “this is working” and “this isn’t enough”… with no clear path forward?



All episodes of On The Pen GLP-1 News

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.